Immunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective study

BACKGROUND: A significant decrease in antibody titres several months after COVID-19 primary vaccination in end-stage kidney disease (ESKD) patients receiving maintenance haemodialysis has recently been reported. The waning in antibody titres has led to the recommendations for a booster dose to incre...

Descripción completa

Detalles Bibliográficos
Autores principales: Puspitasari, Metalia, Sattwika, Prenali D., Hidayat, Auliana R. P., Wijaya, Wynne, Wardhani, Yulia, Intansari, Umi S., Kertia, Nyoman, Purwanto, Bambang, Thobari, Jarir At
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10226875/
https://www.ncbi.nlm.nih.gov/pubmed/37248445
http://dx.doi.org/10.1186/s12882-023-03218-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10226875/
https://www.ncbi.nlm.nih.gov/pubmed/37248445
http://dx.doi.org/10.1186/s12882-023-03218-x

Ejemplares similares